Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.

@article{Max2014Indoleamine23dioxygenaseIA,
  title={Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.},
  author={Daniela Max and Caspar D. K{\"u}hn{\"o}l and Stefan E. G. Burdach and Liguo Niu and Martin Sebastian Staege and J. F{\"o}ll},
  journal={Anticancer research},
  year={2014},
  volume={34 11},
  pages={6431-41}
}
BACKGROUND/AIM Interleukin-2 (IL2) transgenic Ewing sarcoma cells reduce tumor growth in vivo and in vitro. In the present study we analyzed the expression of immune suppressive indoleamine-2,3-dioxygenase (IDO) in this model. MATERIALS AND METHODS Expression of IDO was analyzed by polymerase chain reaction. The impact of the cluster of differentiation 137 (CD137)/CD137 ligand (CD137L) co-stimulatory system on expression of IDO and different cytokines was analyzed both in vivo and in vitro… CONTINUE READING